GlassScriptPhysician profile
Ronald C Mcgaugh
NPI 1023200383
$7,306.51
in general payments reported to CMS, 2019-2025
39 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $1,489 · 2021: $1,315 · 2022: $820 · 2023: $1,529 · 2024: $954 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,953.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,260.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $718.55 | 2021-2025 | |
| Pfizer INC. | $549.61 | 2019-2025 | |
| Lilly USA, LLC | $506.93 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $444.22 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $340.32 | 2023-2025 | Farxiga, Airsupra, Lokelma |
| Janssen Pharmaceuticals, INC | $306.47 | 2021-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $306.02 | 2022-2025 | Quviviq, Quviviq |
| Biohaven Pharmaceuticals, INC. | $299.16 | 2021 | |
| Amgen INC. | $241.58 | 2019-2022 | |
| Allergan, INC. | $216.31 | 2019-2020 | |
| Exact Sciences Corporation | $201.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $179.85 | 2020-2023 | |
| Amarin Pharma, INC. | $154.64 | 2020-2021 | |
| Genentech USA, INC. | $128.70 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $119.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.79 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $114.70 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $109.15 | 2019-2024 | Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.31 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $96.69 | 2019-2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $89.42 | 2019-2024 | Veozah |
| Horizon Therapeutics Plc | $88.27 | 2019-2021 | |
| Esperion Therapeutics, INC. | $74.88 | 2020-2023 | Nexletol |
| Eisai INC. | $61.22 | 2020 | |
| Tms Neurohealth Centers INC. | $49.80 | 2025 | Tms Neurohealth Centers INC. |
| Endo Pharmaceuticals INC. | $48.54 | 2020 | |
| Corium, LLC | $48.37 | 2022-2023 | Azstarys |
| Antares Pharma, INC. | $45.82 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Ironshore Pharmaceuticals INC. | $45.78 | 2024 | |
| Ibsa Pharma INC. | $39.80 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.84 | 2024 | |
| Dexcom, INC. | $35.44 | 2024 | Dexcom G6 Transmitter |
| Globus Medical, INC. | $28.39 | 2025 | Senza |
| Gilead Sciences, INC. | $28.34 | 2019 | |
| Shire North American Group INC | $27.67 | 2019 | |
| Nevro Corp. | $20.76 | 2024 | Senza |
| Paratek Pharmaceuticals, INC. | $13.32 | 2024 | Nuzyra |
| Circassia INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mcgaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.